<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02034708</url>
  </required_header>
  <id_info>
    <org_study_id>DGD-44-058</org_study_id>
    <nct_id>NCT02034708</nct_id>
  </id_info>
  <brief_title>Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors</brief_title>
  <acronym>REMIND</acronym>
  <official_title>Intra-individual Cross-over Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/ Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guerbet</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guerbet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate non-inferiority of Dotarem®-enhanced MRI as
      compared to Gadovist®/ Gadavist®-enhanced MRI in the diagnosis of brain tumors in terms of
      overall lesion visualization and characterization (off-site assessment).

      270 patients will be randomized between 2 arms defining the sequence of administration of the
      contrast agents at the dose of 0.1mmol/kg, with a minimum of 48 hours and a maximum of 14
      days in between.

      Each patient will, therefore, receive two MRI during his/her participation in the study.

      The two arms consist in :

        -  Dotarem® in the first MRI, then Gadovist®/Gadavist® in the second MRI.

        -  Gadovist®/Gadavist® in the first MRI, then Dotarem® in the second MRI.

      Contrast-enhanced MRIs will be performed on 1.5 or 3 Tesla systems.

      MRI examinations will be evaluated centrally by blinded independent readers for the main
      evaluation criterion.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients With Overall Lesion Visualization and Characterization Scored as Good or Excellent</measure>
    <time_frame>Up to 15 days after randomization</time_frame>
    <description>Overall lesion visualization and characterization, based on assessment of the primary or largest lesion if there is more than one lesion present, was assessed by 3 independent off-site readers on a 4-point scale:
0. Poor: does not allow adequate visualization and characterization of the lesion; 1. Fair: allows partial visualization and characterization of the lesion ; 2. Good: allows adequate visualization and characterization of the lesion; 3. Excellent: allows excellent visualization and characterization of the lesion.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">279</enrollment>
  <condition>Primary Brain Tumor</condition>
  <arm_group>
    <arm_group_label>Dotarem®/Gadovist®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dotarem®-enhanced MRI, then Gadovist®/Gadavist®-enhanced MRI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gadovist®/Dotarem®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gadovist®/Gadavist®-enhanced MRI then Dotarem® enhanced MRI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dotarem®</intervention_name>
    <description>Dotarem® 0.1 mmoL/kg (0.2 mL/kg), intravenous (I.V.) bolus.</description>
    <arm_group_label>Dotarem®/Gadovist®</arm_group_label>
    <arm_group_label>Gadovist®/Dotarem®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gadovist®/Gadavist®</intervention_name>
    <description>Gadovist®/Gadavist®, 0.1mmol/kg (0.1mL/kg), intravenous (I.V.) bolus.</description>
    <arm_group_label>Dotarem®/Gadovist®</arm_group_label>
    <arm_group_label>Gadovist®/Dotarem®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female or male adult patient (patient having reached legal majority age)

          -  Patient with known or highly suspected primary intracranial tumors (intra-axial or
             extra-axial) detected by previous CT or MRI examination who are scheduled to undergo a
             routine contrast-enhanced MRI

          -  Female patient must have effective contraception throughout the study and must have a
             negative urine pregnancy test at inclusion, or be surgically sterilized, or
             post-menopausal (minimum 12 months of amenorrhea)

          -  Patient having provided his/her written informed consent to participate in the trial
             prior to any study-related procedure being conducted

          -  Patient with national health insurance (according to local regulatory requirements)

        Exclusion Criteria:

          -  Patient with rapidly evolving brain tumor that could change in appearance between the
             time of the two study MRI examinations.

          -  Patient undergoing current or recent treatment within past 6 weeks or scheduled for
             any treatment that could results in changes of lesion appearance between the two study
             examinations. This would include, but not restricted to, the following: current or
             recent radiation therapy, surgery, starting or recent chemotherapy.

          -  Patient with a contraindication to MRI (e.g., pacemaker, aneurysm clip, severe
             claustrophobia, infusion pumps, cochlear implants metallic or others according to the
             imaging site standard practice)

          -  Patient with known severely impaired renal function (defined as eGFR MDRD&lt; 30
             ml/min/1.73m2)

          -  Patient with known Class III/IV congestive heart failure according to the New York
             Heart Association classification

          -  Patient with known severe adverse drug reaction or contraindication to
             Gadolinium-Based Contrast Agent

          -  Patient having received any contrast agent within 48 hours prior to first study
             contrast agent injection scheduled for the study and patient expected to receive any
             other contrast agent within 24 hours of the last study contrast agent injection

          -  Patient presenting with any condition which, based on the investigator's clinical
             judgment, would prevent the patient from completing all trial assessments and visits

          -  Patient under guardianship and/or unable or unwilling to cooperate with the
             requirements of this trial

          -  Pregnant or breast feeding female patient

          -  Patient already included in this trial

          -  Patient included in another clinical trial involving an IMP within 30 days before the
             first investigational contrast agent injection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth Maravilla, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Washington Medical Center, Seattle, USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arizona Medical Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>AZ 85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University School Of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infinity Clinical Research, LLC</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>FL 33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quest Research Institute</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spectrum Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winthrop University Hospital Clinical Trials Center</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>NY 11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MUSC (Medical University of South Carolina)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UVM MRI Center for Biomedical Imaging</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Abood Shaio</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Cardioinfantil Instituto de Cardiologia</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cancerologia</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico Imbanaco</name>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Instituto de Alta Tecnologia Medica de Antioquia IATM</name>
      <address>
        <city>Medellin</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pablo Tobon Uribe</name>
      <address>
        <city>Medellin</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungbuk National University</name>
      <address>
        <city>Cheongju-si</city>
        <state>Chungcheongbuk-do</state>
        <zip>361-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonbuk national Univ Hosp</name>
      <address>
        <city>Jeonju-si</city>
        <state>Jeollabuk-do</state>
        <zip>561-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul St.Mary Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Seocho-gu</state>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan medical center</name>
      <address>
        <city>Seoul</city>
        <state>Songpa-Gu</state>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morales Vargas Centro de Investigación S.C.</name>
      <address>
        <city>Leon</city>
        <state>Guanajuato</state>
        <zip>37000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Neurologico ABC</name>
      <address>
        <city>Mexico</city>
        <state>Mexico Distrito Federal</state>
        <zip>5300</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr. Jose Eleuterio Gonzalez</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64020</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winsett Rethman S.A. de C.V.</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital CIMA</name>
      <address>
        <city>Chihuahua</city>
        <zip>31238</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Regiomontano de Investigacion S.C.</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute S.C.</name>
      <address>
        <city>Tlanepantla</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2014</study_first_submitted>
  <study_first_submitted_qc>January 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2014</study_first_posted>
  <results_first_submitted>September 2, 2016</results_first_submitted>
  <results_first_submitted_qc>September 2, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 25, 2016</results_first_posted>
  <last_update_submitted>November 9, 2016</last_update_submitted>
  <last_update_submitted_qc>November 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary brain tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Adult patients with known or highly suspected primary intracranial tumors and scheduled for a Dotarem®-enhanced MRI were recruited in 27 active centers in 4 countries (Colombia, South Korea, Mexico and United States) from June 2014 to September 2015.</recruitment_details>
      <pre_assignment_details>279 patients signed an informed consent for the study and therefore were considered as included. From these 279 patients, 11 did not receive any injection : 4 for consent withdrawn, 3 for deviation from plan specified in the protocol, 2 for adverse events, 1 at the investigator's discretion and 1 for other reason.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dotarem®/Gadovist®</title>
          <description>Dotarem®-enhanced MRI, then Gadovist®/Gadavist®-enhanced MRI
Dotarem®: 0.1 mmoL/kg (0.2 mL/kg), intravenous (I.V.) bolus.
Gadovist®/Gadavist®: 0.1mmol/kg (0.1mL/kg), intravenous (I.V.) bolus.</description>
        </group>
        <group group_id="P2">
          <title>Gadovist®/Dotarem®</title>
          <description>Gadovist®/Gadavist®-enhanced MRI then Dotarem® enhanced MRI
Dotarem®: 0.1 mmoL/kg (0.2 mL/kg), intravenous (I.V.) bolus.
Gadovist®/Gadavist®: 0.1mmol/kg (0.1mL/kg), intravenous (I.V.) bolus.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Contrast Agent Injection (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="138"/>
                <participants group_id="P2" count="130"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="138"/>
                <participants group_id="P2" count="130"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Wash-out (From 2 Days up to 14 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="138"/>
                <participants group_id="P2" count="130"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="129"/>
                <participants group_id="P2" count="120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>other reason</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Contrast Agent Injection (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="129"/>
                <participants group_id="P2" count="120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="129"/>
                <participants group_id="P2" count="120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All patients receiving at least one injection of contrast agent and with one valid assessment of the primary outcome</population>
      <group_list>
        <group group_id="B1">
          <title>Dotarem®/Gadovist®</title>
          <description>Dotarem®-enhanced MRI, then Gadovist®/Gadavist®-enhanced MRI
Dotarem®: 0.1 mmoL/kg (0.2 mL/kg), intravenous (I.V.) bolus.
Gadovist®/Gadavist®: 0.1mmol/kg (0.1mL/kg), intravenous (I.V.) bolus.</description>
        </group>
        <group group_id="B2">
          <title>Gadovist®/Dotarem®</title>
          <description>Gadovist®/Gadavist®-enhanced MRI then Dotarem® enhanced MRI
Dotarem®: 0.1 mmoL/kg (0.2 mL/kg), intravenous (I.V.) bolus.
Gadovist®/Gadavist®: 0.1mmol/kg (0.1mL/kg), intravenous (I.V.) bolus.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="138"/>
            <count group_id="B2" value="130"/>
            <count group_id="B3" value="268"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.9" spread="15.2"/>
                    <measurement group_id="B2" value="54.4" spread="15.1"/>
                    <measurement group_id="B3" value="53.6" spread="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="172"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Colombia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg per square metre</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.71" spread="5.35"/>
                    <measurement group_id="B2" value="27.62" spread="5.23"/>
                    <measurement group_id="B3" value="27.66" spread="5.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients With Overall Lesion Visualization and Characterization Scored as Good or Excellent</title>
        <description>Overall lesion visualization and characterization, based on assessment of the primary or largest lesion if there is more than one lesion present, was assessed by 3 independent off-site readers on a 4-point scale:
0. Poor: does not allow adequate visualization and characterization of the lesion; 1. Fair: allows partial visualization and characterization of the lesion ; 2. Good: allows adequate visualization and characterization of the lesion; 3. Excellent: allows excellent visualization and characterization of the lesion.</description>
        <time_frame>Up to 15 days after randomization</time_frame>
        <population>Patients with at least one valid assessment of the primary outcome and without major protocol deviation</population>
        <group_list>
          <group group_id="O1">
            <title>Gadovist® (Reader 1)</title>
            <description>Patients who received Gadovist® Results for reader 1</description>
          </group>
          <group group_id="O2">
            <title>Dotarem® (Reader 1)</title>
            <description>Patients who received Dotarem® Results for reader 1</description>
          </group>
          <group group_id="O3">
            <title>Gadovist® (Reader 2)</title>
            <description>Patients who received Gadovist® Results for reader 2</description>
          </group>
          <group group_id="O4">
            <title>Dotarem® (Reader 2)</title>
            <description>Patients who received Dotarem® Results for reader 2</description>
          </group>
          <group group_id="O5">
            <title>Gadovist® (Reader 3)</title>
            <description>Patients who received Gadovist® Results for reader 3</description>
          </group>
          <group group_id="O6">
            <title>Dotarem® (Reader 3)</title>
            <description>Patients who received Dotarem® Results for reader 3</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Overall Lesion Visualization and Characterization Scored as Good or Excellent</title>
          <description>Overall lesion visualization and characterization, based on assessment of the primary or largest lesion if there is more than one lesion present, was assessed by 3 independent off-site readers on a 4-point scale:
0. Poor: does not allow adequate visualization and characterization of the lesion; 1. Fair: allows partial visualization and characterization of the lesion ; 2. Good: allows adequate visualization and characterization of the lesion; 3. Excellent: allows excellent visualization and characterization of the lesion.</description>
          <population>Patients with at least one valid assessment of the primary outcome and without major protocol deviation</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="234"/>
                <count group_id="O2" value="234"/>
                <count group_id="O3" value="234"/>
                <count group_id="O4" value="234"/>
                <count group_id="O5" value="234"/>
                <count group_id="O6" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.0"/>
                    <measurement group_id="O2" value="96.2"/>
                    <measurement group_id="O3" value="93.2"/>
                    <measurement group_id="O4" value="90.6"/>
                    <measurement group_id="O5" value="99.6"/>
                    <measurement group_id="O6" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From patient inclusion up to 30 min after last contrast agent injection</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dotarem®</title>
          <description>Patients who received Dotarem®</description>
        </group>
        <group group_id="E2">
          <title>Gadovist®</title>
          <description>Patients who received Gadovist®</description>
        </group>
        <group group_id="E3">
          <title>Total</title>
          <description>Patients who received at least one injection of contrast agent</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Aggravation of existing disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="259"/>
                <counts group_id="E3" subjects_affected="63" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="258"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="259"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Infrequent bowel movements</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="258"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="259"/>
                <counts group_id="E3" events="25" subjects_affected="20" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Medical device pain</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="258"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="259"/>
                <counts group_id="E3" events="32" subjects_affected="17" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Injection site coldness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Injection site paraesthesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="258"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Catheter site related reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Drug ineffective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Feeling cold</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Injection site inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Injection site rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="259"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="258"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="259"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="258"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="259"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="258"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Each investigator agrees not to publish/present the results of the study main criterion involving only the patients included in his/her center. Publications on specific topics can be performed only after main publication.The sponsor can review the publication at least 30 days before the submission to the scientific review and any abstract project at least 10 working days before submission to the congress scientific committee. The sponsor can require changes to the publication or the abstract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Corinne Dubourdieu, PharmD, Head of Clinical Projects and Medical</name_or_title>
      <organization>Guerbet</organization>
      <phone>+33 (0) 1 45 91 51 84</phone>
      <email>corinne.dubourdieu@guerbet-group.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

